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Artemisinin-based combination therapies (ACTs) are the cornerstone for the treatment of malaria. However, confirmed
resistance to artemisinins in South-East Asia, and reports of reduced efficacy of ACTs raise major concerns for malaria
treatment and control. Without new drugs to replace artemisinins, it is essential to define dosing strategies that
maximize therapeutic efficacy, limit the spread of resistance, and preserve the clinical value of ACTs. It is important to
determine the extent to which reduced efficacy of ACTs reflects true resistance versus sub-optimal dosing, and quantify
other factors that determine treatment failure. Pooled analyses of individual patient data from multiple clinical trials, by
investigators in the Worldwide Antimalarial Resistance Network, have shown high overall efficacy for three widely used
ACTs, artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine. Analyses also highlight
that suboptimal dosing leads to increased risk of treatment failure, especially among children. In the most recent
study, an analysis of clinical trials of artesunate-amodiaquine, widely used among children in Africa, revealed a
superior efficacy for fixed-dose combination tablets compared to loose non-fixed dose combinations. This highlights
the benefits of fixed-dose combinations as a practical strategy for ensuring optimal antimalarial dosing and
maximizing efficacy.
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Keywords: Amodiaquine, Artemisinins, Artesunate, Drug resistance, MalariaIntroduction
Artemisinin-based combination therapies (ACTs) have
made a major contribution to the reduction in global
malaria morbidity and mortality since their use became
widespread approximately 10 years ago. ACTs are rec-
ommended by the WHO as the first-line treatment of
uncomplicated and severe P. falciparum malaria in all
areas in which malaria is endemic [1], and have been
adopted as first-line therapy in many countries. Around
390 million ACT treatments are procured annually [2].
Drugs of the artemisinin group (artesunate, artemether,
and dihydroartemisinin are the most used) are the most
parasiticidal of established antimalarials and rapidly clear
parasitemia, and are well tolerated with a good safety pro-
file. However, artemisinin drugs have a short half-life
(<1 hour) and when used on their own to treat malaria re-
quire 7- to 10-day treatment to achieve high cure rates,
which impacts on adherence. Therefore, artemisinins are* Correspondence: beeson@burnet.edu.au
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unless otherwise stated.typically combined with a long-acting partner drug (e.g.,
lumefantrine, amodiaquine, piperaquine) in order to
achieve high cure rates with a 3-day treatment regimen.
The combination of artemether-lumefantrine is the most
widely used ACT, and is highly efficacious [3]. Artesunate-
amodiaquine (AS-AQ) is widely used for malaria therapy
in Africa, particularly among children, and is the second
most used ACT globally.
The global threat of drug resistance
Unfortunately, the early signs of artemisinin resistance
have emerged in South-East Asia threatening recent
gains and milestones in the treatment and control of
malaria [4,5]. Resistance to artemisinins has been re-
cently associated with a mutation in the kelch13 gene
(gene ID PF3D7_1343700) [6-8], and the identification
of this genetic marker will greatly facilitate resistance
surveillance [4,9]. Emerging resistance was initially iden-
tified as delayed parasite clearance rates following treat-
ment with artemisinin-based therapies [5]. Confirmed
partial artemisinin resistance is now defined by the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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associated mutations, all of whom have been found, after
treatment with ACT or artesunate monotherapy, to have
either persistent parasitaemia by microscopy on day 3,
or a parasite clearance half-life of ≥5 hours. Reflecting
the importance of this issue, the WHO launched its Glo-
bal Plan on Artemisinin Resistance Containment in 2011
with a specific emergency response to artemisinin resist-
ance in the Greater Mekong sub-region in 2013. In
addition, there are reports of reduced clinical efficacy of
ACT therapy after 28 days of follow-up in some settings
[10-15]. It is important to determine the extent to which
this reduced efficacy reflects true resistance versus sub-
optimal dosing, or other factors. The development of
widespread resistance has limited the utility of numerous
other antimalarials that were previously widely used,
such as chloroquine and sulfadoxine-pyrimethamine,
providing a sobering reminder of the potential impact of
evolving resistance to drugs in current use. With no new
drugs immediately available to replace artemisinins, it is
essential to optimize and define dosing strategies to en-
sure maximum therapeutic efficacy of ACTs, limit the
spread of resistance, and extend the clinical life of ACTs.
Identifying factors associated with reduced
efficacy: importance of dosing strategies
A new study from the Worldwide Antimalarial Resist-
ance Network (WWARN) investigated risk factors for
treatment failure with AS-AQ therapy [16]. Reduced
antimalarial efficacy of AS-AQ has been reported in
some studies, but it is unlikely that drug resistance is the
major factor explaining this; confirmed AS resistance
has not yet been reported in Africa [4,17] and reduced
efficacy of AS-AQ has been observed between studies
within the same region (which should have similar rates
of potential AQ resistance) [18-20]. It was hypothesised
that differences in doses or formulations impacted on
the antimalarial efficacy of AS-AQ. To investigate this,
the WWARN investigator group conducted a systematic
review and meta-analysis of individual patient data in-
cluding published and unpublished antimalarial thera-
peutic efficacy trials that included at least one AS-AQ
arm, conducted between 1999 and 2012.
AS-AQ is available in three different body-weight-
adjusted drug formulations: fixed-dose combinations,
loose non-fixed dose combinations, and co-blistered
non-fixed-dose combinations. All of these combinations
aim at delivering 12 mg/kg of AS over 3 days, but the
total target dose of AQ ranges from 25 to 30 mg/kg for
loose non-fixed dose combinations and is 30 mg/kg for
co-blistered non-fixed-dose combinations and fixed-dose
combinations. The WWARN study included 43 trials
(9,106 treatments), of which 39 trials (95% of subjects)
were conducted in Africa, as well as 3 in Asia and 1 inSouth America, and the great majority were children
(87.5% were <12 years old) [16]. The authors investi-
gated the relationship between these different drug for-
mulations and the actual dose of AQ received as well as
treatment success, including parasitemia at 28 days and
potential recrudescence in infants, children, and adults.
Studies of this size are needed in order to have sufficient
power to examine these questions when treatment effi-
cacy rates are high, as they are with ACTs, emphasising
the importance of multisite collaborative studies.
Arguably, the most important finding was that fixed-
dose combinations were associated with the highest AS-
AQ treatment efficacy in all age groups, including in
children less than 5 years of age, independently of high
baseline parasitemia and young age. The fixed dose com-
bination of AS-AQ was developed using weight-for-age
values from malaria endemic countries, to ensure opti-
mal dosing [21,22]. Loose non-fixed-dose combinations,
with an AQ target dose of 25 mg/kg, were associated
with a 3.5-fold greater risk of recrudescence by day 28.
The implication of these findings on the treatment of
paediatric malaria reinforces initiatives to promote the
distribution and implementation of fixed-dose regimens
for therapy. The use of co-blistered and loose non-fixed-
dose combinations may require splitting of tablets when
treating children, potentially leading to suboptimal AQ
dosing and therefore lower treatment efficacy. The use of
fixed-dose AS-AQ formulations, including paediatric tab-
lets, would circumvent this issue, leading to optimal AQ
dosing and high treatment efficacy. As such, the treatment
of uncomplicated P. falciparum malaria using fixed-dose
AS-AQ formulations should be promoted for national
treatment guidelines.
The study also found that the risk of recrudescence
after AS-AQ treatment was higher among young chil-
dren (<12 years old), those with a high baseline parasit-
emia, and in Asian studies compared to African. This
may be reflective of the overall higher level of AQ resist-
ance in Asia; however, given the small number of sub-
jects from Asian trials, further studies are needed to
examine this. The potentially crucial impact of P. falcip-
arum resistance to AQ could not be evaluated in this
study and further studies incorporating molecular
markers of AQ resistance are warranted. Resistance to
AQ is associated with mutations in the pfcrt and pfmdr
genes [23,24], which are prevalent in most endemic
countries [25]. It will be interesting to see the results
from an AQ pharmacokinetic-pharmacodynamic analysis
by WWARN, which is examining the effects of drug for-
mulation and dose, and host age and nutritional status
on AQ drug concentrations. Since most of the therapeutic
efficacy trials analysed were performed in sub-Saharan
Africa, more data from Asian and South American trials
are needed in order to generalise these findings to
Box 1: Key points
Antimalarial drugs and resistance
 The WHO recommends artemisinin combination therapies
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varied degrees of AQ resistance. Regarding side effects,
there was no evidence for a higher risk of neutropenia
(which is associated with AQ use) with the higher AQ
dose, but higher rates of vomiting and diarrhoea were
observed.(ACT) as the first-line treatment of malaria
 Around 390 million courses of ACTs procured annually 1
 Emerging resistance to ACTs: Resistance confirmed in five
countries in the Greater Mekong sub-region
 Suspected artemisinin resistance is defined as failure to clear
parasitemia within 3 days of commencing treatment, or a
parasite clearance half-life of ≥5 hours
 Resistance to ACTs is associated with mutations in kelch13
gene
 Resistance to other antimalarials is widespread (e.g.
chloroquine, amodiaquine, sulfadoxine-pyrimethamine)
 Resistance to amodiaquine and chloroquine is associated
with mutations in the pfcrt and pfmdr1 genes
 Ensuring effective dosing is crucial to maximize efficacy and
to protect against the further development and spread of
resistance
WWARN study on artesunate-amodiaquine (AS-AQ) 2
 AS-AQ is widely used in Africa, and is the second most
widely used ACT
 AS-AQ Previously shown to have high efficacy when
administered correctly
 WWARN study performed an individual patient meta-
analysis using data from 43 studies (39 studies in Africa)
with over 9,000 treatments, predominantly in childrenOther studies investigating the importance of
correct dosing with ACTs
There have been two related studies performed by
WWARN investigators on the efficacy of other ACTs,
highlighting the importance of optimal dosing. Dihy-
droartemisinin-piperaquine is another widely used ACT,
and risk factors for recrudescence after treatment were
examined in a pooled analysis of individual patient data
from 26 efficacy studies (7,072 patients) [26]. Overall
efficacy was high (97.7%), but was significantly reduced
in those who received lower doses of piperaquine. Of
concern was that 28.6% of young children (1 to 5 years
old) received a piperaquine dose below the lower limit
recommended by the WHO, further highlighting the
need for strategies to ensure optimal dosing for malaria
treatment. Recently, a pooled analysis of individual
patient data from efficacy studies of artemether-
lumefantrine included 61 studies and 14,327 patients [3];
overall, day 28 efficacy was very high (97.6%). Analysis
revealed that a higher dose of artemether was associated
with a lower risk of persistent parasitaemia on day 1 and
lower gametocyte carriage rates, which may be import-
ant for reducing transmission. In Asia, lower doses of
lumefantrine were associated with reduced efficacy
among children weighing 10 to 15 kg. The risk of treat-
ment failure was also higher among malnourished chil-
dren aged 1 to 3 years in Africa. Study evaluated the impact of different dosing strategies on
therapeutic efficacy
 Fixed-dose and co-blistered non-fixed dose combinations
had high efficacy (98%)
 Use of loose tablets at non-fixed dose had significantly lower
efficacy (up to 3.5-fold higher risk of treatment failure)
 Findings highlight the benefit of fixed dose combinations
and support this strategy in the treatment and control of
malaria
 Increased risk of recrudescence among young children, those
with high baseline parasitemia, and among trials conducted
in Asia
1. Based on WHO figures from 2013.
2. See reference [16]Conclusions
In an era of emerging artemisinin resistance, and the
push for malaria elimination in many regions, studies
such as that of the WWARN collaboration provide im-
portant data to inform policymakers and clinicians to
optimise antimalarial therapies to maximize efficacy and
help reduce the evolution of resistance (see Box 1 for a
summary of key points). These findings provide further
support for international collaborative networks and
data sharing arrangements to address major challenges
in global health, and the approach used for malaria has
strong relevance to antimicrobial therapy and resistance
more broadly. Individual patient meta-analyses of thera-
peutic efficacy studies are considered the strongest form
of clinical evidence, and are essential to inform antimal-
arial policy and clinical treatment guidelines to ensure
the rapid and effective treatment of malaria cases.
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